1887

Abstract

Mice were immunized intramuscularly with free recombinant hepatitis C virus (HCV) NS3 (non-structural protein 3) protein, liposomes encapsulating rNS3 or rNS3 and CpG mixture, liposomes co-encapsulating rNS3 and CpG or liposomes co-encapsulating rNS3 and GpC. Liposomes co-encapsulating rNS3 and CpG induced a much higher titre of anti-HCV NS3 IgG and the dominant IgG subtype was IgG2a. Liposomes co-encapsulating rNS3 and GpC also induced high levels of anti-HCV NS3 IgG antibody, but the dominant IgG subtype was still IgG1, the same as in free HCV/NS3 immunized mice. Liposomes encapsulating rHCV NS3 and the mixture of rHCV NS3 and CpG did not increase the antibody response but switched the IgG subtype. A cytokine profile analysis revealed that the levels of Th1 cytokines in the mice immunized with liposomes co-encapsulating rHCV NS3 and CpG were significantly higher than in other mice while the levels of Th2 cytokine were significantly lower than in the mice immunized with naked rNS3. IL-12 in the mice immunized with liposome-NS3-CpG was significantly higher than in other mice. In conclusion, liposomes co-encapsulating HCV NS3 and CpG are a good candidate vaccine to induce strong Th1 immune responses against hepatitis C viruses.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.79896-0
2004-06-01
2020-01-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/6/vir851545.html?itemId=/content/journal/jgv/10.1099/vir.0.79896-0&mimeType=html&fmt=ahah

References

  1. Arribillaga, L., de Cerio, A. L., Sarobe, P. & 9 other authors ( 2002; ). Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 21, 202–210.[CrossRef]
    [Google Scholar]
  2. Brazolot-Millan, C. L. B., Weeratna, R., Krieg, A. M., Siegrist, C. A. & Davis, H. L. ( 1998; ). CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A 95, 15553–15558.[CrossRef]
    [Google Scholar]
  3. Brinster, C., Muguet, S., Lone, Y. C., Boucreux, D., Renard, N., Fournillier, A., Lemonnier, F. & Inchauspe, G. ( 2001; ). Different hepatitis C virus nonstructural protein 3 (NS3)-DNA-expressing vaccines induce in HLA-A2·1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 34, 1206–1217.[CrossRef]
    [Google Scholar]
  4. Brinster, C., Chen, M., Boucreux, D., Paranhos-Baccala, G., Liljestrom, P., Lemmonier, F. & Inchauspe, G. ( 2002; ). Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 83, 369–381.
    [Google Scholar]
  5. Carstens, C. P. ( 2003; ). Use of tRNA-supplemented host strains for expression of heterologous genes in E. coli. Methods Mol Biol 205, 225–233.
    [Google Scholar]
  6. Cho, J. H., Lee, S. W. & Sung, Y. C. ( 1999; ). Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine 17, 1136–1144.[CrossRef]
    [Google Scholar]
  7. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. ( 1989; ). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359–362.[CrossRef]
    [Google Scholar]
  8. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. & Harding, C. V. ( 1997; ). CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186, 1623–1631.[CrossRef]
    [Google Scholar]
  9. Cohen, J. ( 1999; ). The scientific challenge of hepatitis C. Science 285, 26–30.[CrossRef]
    [Google Scholar]
  10. Cramp, M. E., Rossol, S., Chokshi, S., Carucci, P., Williams, R. & Naoumov, N. V. ( 2000; ). Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118, 346–355.[CrossRef]
    [Google Scholar]
  11. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. & Krieg, A. M. ( 1998; ). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870–876.
    [Google Scholar]
  12. Diepolder, H. M., Zachoval, R. M., Hoffmann, R. M., Wierenga, E. A., Santantonia, T., Jung, M. C., Eichenlaub, D. & Pape, G. R. ( 1995; ). Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346, 1006–1007.[CrossRef]
    [Google Scholar]
  13. Diepolder, H. M., Gerlach, J.-T., Zachoval, R. M. & 9 other authors ( 1997; ). Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71, 6011–6019.
    [Google Scholar]
  14. Dow, S. W., Fradkin, L. G., Liggitt, D. H., Willson, A. P., Heath, T. D. & Potter, T. A. ( 1999; ). Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163, 1552–1561.
    [Google Scholar]
  15. Encke, J., zu Putlitz, J., Geissler, M. & Wands, J. R. ( 1998; ). Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 161, 4917–4923.
    [Google Scholar]
  16. Frelin, L., Alheim, M., Chen, A., Soderholm, J., Rozell, B., Barnfield, C., Liljestrom, P. & Sallberg, M. ( 2003; ). Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther 10, 686–699.[CrossRef]
    [Google Scholar]
  17. Gordon, E. J., Bhat, R., Liu, Q., Wang, Y.-F., Tackney, C. & Prince, A. M. ( 2000; ). Immune responses to hepatitis C virus structural and nonstructral proteins induced by plasmid DNA immunizations. J Infect Dis 181, 42–50.[CrossRef]
    [Google Scholar]
  18. Hemmi, H., Takeuchi, O., Kawai, T. & 8 other authors ( 2000; ). A toll-like receptor recognizes bacterial DNA. Nature 408, 740–745.[CrossRef]
    [Google Scholar]
  19. Jiao, X., Wang, R. Y.-H., Feng, Z., Alter, H. J. & Shih, J. W.-K. ( 2003; ). Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 of by cationic liposome encapsulated DNA immunization. Hepatology 37, 452–460.[CrossRef]
    [Google Scholar]
  20. Jiao, X., Wang, R. Y.-H., Feng, Z., Hu, G., Alter, H. J. & Shih, J. W.-K. ( 2004; ). DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response. J Viral Hepat 11, 18–26.[CrossRef]
    [Google Scholar]
  21. Kane, J. F. ( 1995; ). Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol 6, 494–500.[CrossRef]
    [Google Scholar]
  22. Kirby, C. & Gregoriadis, G. ( 1984; ). Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 11, 979–984.
    [Google Scholar]
  23. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J. & Krieg, A. M. ( 1996; ). CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci U S A 93, 2879–2883.[CrossRef]
    [Google Scholar]
  24. Klinman, D. M., Barnhart, K. M. & Conover, J. ( 1999; ). CpG motifs as immune adjuvants. Vaccine 17, 19–25.[CrossRef]
    [Google Scholar]
  25. Kourilsky, P. & Truffa-Bachi, P. ( 2001; ). Cytokine fields and the polarization of the immune response. Trends Immunol 22, 502–509.[CrossRef]
    [Google Scholar]
  26. Krieg, A. M. ( 1996; ). Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol 4, 73–76.[CrossRef]
    [Google Scholar]
  27. Krieg, A. M. ( 1999; ). Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489, 107–116.[CrossRef]
    [Google Scholar]
  28. Krieg, A. M. ( 2000; ). Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol 22, 97–105.[CrossRef]
    [Google Scholar]
  29. Kusakabe, K., Xin, K. Q., Katoh, H. & 9 other authors ( 2000; ). The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 164, 3102–3111.[CrossRef]
    [Google Scholar]
  30. Lanuti, M., Rudginsky, S., Force, S. D. & 7 other authors ( 2000; ). Cationic lipid: bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 60, 2955–2963.
    [Google Scholar]
  31. Lazdina, U., Hultgren, C., Frelin, L. & 8 other authors ( 2001; ). Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol 82, 1299–1308.
    [Google Scholar]
  32. Li, W. M., Bally, M. B. & Schutze-Redelmeier, M. P. ( 2001; ). Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20, 148–157.[CrossRef]
    [Google Scholar]
  33. McHutchison, J. G., Gorden, S. C., Schiff, E. R. & 7 other authors ( 1998; ). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 339, 1485–1492.[CrossRef]
    [Google Scholar]
  34. Moldoveanu, Z., Love-Homan, L., Huang, W. Q. & Krieg, A. M. ( 1998; ). CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216–1224.[CrossRef]
    [Google Scholar]
  35. Petsch, D. & Anspach, F. B. ( 2000; ). Endotoxin removal from protein solutions. J Biotechnol 76, 97–119.[CrossRef]
    [Google Scholar]
  36. Pisetsky, D. S. ( 1996; ). Immune activation by bacterial DNA: a new genetic code. Immunity 5, 303–310.[CrossRef]
    [Google Scholar]
  37. Poynard, T., Marcellin, P., Lee, S. S. & 8 other authors ( 1998; ). Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426–1432.[CrossRef]
    [Google Scholar]
  38. Rehermann, B. & Chisari, F. V. ( 2000; ). Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 242, 299–325.
    [Google Scholar]
  39. Shevach, E. M. ( 1994; ). ELISPOT assay to detect cytokine-secreting murine and human cells. In Current Protocols in Immunology, vol. 1, pp. 6.19.1–6.19.8. Edited by J. E. Coligan, A. M. Kruisbeek, D. H. Margilies & E. M. Shevach. New York: Wiley.
  40. Shirota, H., Sano, K., Kikuchi, T., Tamura, G. & Shirato, K. ( 2000; ). Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol 164, 5575–5582.[CrossRef]
    [Google Scholar]
  41. Shirota, H., Sano, K., Hirasawa, N., Terui, T., Ohuchi, K., Hattori, T., Shirato, K. & Tamura, G. ( 2001; ). Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 167, 66–74.[CrossRef]
    [Google Scholar]
  42. Simon, B. E., Cornell, K. A., Clark, T. R., Chou, S., Rosen, H. R. & Barry, R. A. ( 2003; ). DNA vaccination protects mice against challenge with listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun 71, 6372–6380.[CrossRef]
    [Google Scholar]
  43. Stratton, K. R., Durch, J. S. & Lawrence, R. S. ( 2000; ). Hepatitis C. In Vaccines for the 21st Century. Washington, DC: National Academy Press.
  44. Sun, S., Kishimoto, H. & Sprent, J. ( 1998a; ). DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med 187, 1145–1150.[CrossRef]
    [Google Scholar]
  45. Sun, S., Zhang, X., Tough, D. F. & Sprent, J. ( 1998b; ). Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 188, 2335–2342.[CrossRef]
    [Google Scholar]
  46. Tighe, H., Takabayashi, K., Schwartz, D. & 7 other authors ( 2000; ). Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 30, 1939–1947.[CrossRef]
    [Google Scholar]
  47. Tsai, S.-L., Liaw, Y.-F., Chen, M.-H., Huang, C.-Y. & Kuo, G. C. ( 1997; ). Detection of type-2 like T-helper cells in hepatitis C virus infection: implication for hepatitis C chronicity. Hepatology 25, 449–458.[CrossRef]
    [Google Scholar]
  48. Wedemeyer, H., Gagneten, S., Davis, A., Bartenschlager, R., Feinstone, S. & Rehermann, B. ( 2001; ). Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 121, 1158–1166.[CrossRef]
    [Google Scholar]
  49. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E. & Krieg, A. M. ( 1997; ). Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 94, 10833–10837.[CrossRef]
    [Google Scholar]
  50. Whitmore, M., Li, S. & Huang, L. ( 1999; ). LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 6, 1867–1875.[CrossRef]
    [Google Scholar]
  51. Zimmermann, S., Egeter, O., Hausmann, S., Lipford, G. B., Rocken, M., Wagner, H. & Heeg, K. ( 1998; ). CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160, 3627–3630.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.79896-0
Loading
/content/journal/jgv/10.1099/vir.0.79896-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error